Literature DB >> 23799328

Body composition in chemotherapy: the promising role of CT scans.

Carla M M Prado1.   

Abstract

PURPOSE OF REVIEW: Reducing cancer-treatment toxicity was a largely ignored research agenda, which is now emerging as an active area of investigation. Studies of human body composition using computerized tomography scans have provided proof-of-concept that variability in drug disposition and toxicity profiles may be partially explained by different features in body composition. RECENT
FINDINGS: Collectively, studies suggest that skeletal muscle depletion (regardless of body weight) is an independent predictor of severe toxicity, affecting cancer treatment and its outcomes. Although precise mechanisms are unknown, pharmacokinetic parameters such as variations in volume of distribution and increased drug exposure may explain such findings.
SUMMARY: Computerized tomography scans are readily available in clinical databases of diagnostic images and provide feasible, reliable, and highly differentiated measurements of body composition. These images should be used to optimize screening and management of patients in order to prevent severe toxicity, and to improve the efficacy and cost-efficiency of chemotherapy treatments.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23799328     DOI: 10.1097/MCO.0b013e328363bcfb

Source DB:  PubMed          Journal:  Curr Opin Clin Nutr Metab Care        ISSN: 1363-1950            Impact factor:   4.294


  19 in total

1.  Measuring Abdominal Circumference and Skeletal Muscle From a Single Cross-Sectional Computed Tomography Image: A Step-by-Step Guide for Clinicians Using National Institutes of Health ImageJ.

Authors:  Sandra L Gomez-Perez; Jacob M Haus; Patricia Sheean; Bimal Patel; Winnie Mar; Vivek Chaudhry; Liam McKeever; Carol Braunschweig
Journal:  JPEN J Parenter Enteral Nutr       Date:  2015-09-21       Impact factor: 4.016

2.  Relationship between skeletal muscle function, body composition, and weight loss in patients with advanced pancreatic and gastrointestinal cancers.

Authors:  P Cresta Morgado; M Daud; M Carballido; G Méndez; S Iseas; V Lobbe; G De Simone; A Navigante
Journal:  Support Care Cancer       Date:  2018-08-18       Impact factor: 3.603

3.  Official position of the Brazilian Association of Bone Assessment and Metabolism (ABRASSO) on the evaluation of body composition by densitometry: part I (technical aspects)-general concepts, indications, acquisition, and analysis.

Authors:  Sergio Setsuo Maeda; Barbara Santarosa Emo Peters; Lígia Araújo Martini; Hannah Karen Moreira Antunes; Maria Cristina Gonzalez; Henrique Pierotti Arantes; Carla M Prado; Camila Lemos Pinto; Iana Mizumukai de Araújo; Francisco José Albuquerque de Paula; Joao Lindolfo Cunha Borges; Ben-Hur Albergaria; Marcela Ushida; Guilherme Cardenaz de Souza; Laura Maria Carvalho de Mendonça; Mirley do Prado; Marcelo de Medeiros Pinheiro
Journal:  Adv Rheumatol       Date:  2022-03-20

4.  Nutritional status assessed by Patient-Generated Subjective Global Assessment is associated with toxicity to chemoradiotherapy in women with cervical cancer: a prospective study.

Authors:  Amanda Pereira Mota; Mariah Azevedo Aredes; Juliana De Oliveira Miguel; Gabriela Villaça Chaves
Journal:  Eur J Clin Nutr       Date:  2022-07-19       Impact factor: 4.884

5.  Postdiagnosis Weight Change and Survival Following a Diagnosis of Early-Stage Breast Cancer.

Authors:  Elizabeth M Cespedes Feliciano; Candyce H Kroenke; Patrick T Bradshaw; Wendy Y Chen; Carla M Prado; Erin K Weltzien; Adrienne L Castillo; Bette J Caan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-08-26       Impact factor: 4.254

6.  Making the most of the imaging we have: using head MRI to estimate body composition.

Authors:  C M Lack; G J Lesser; U N Umesi; J Bowns; M Y Chen; D Case; R C Hightower; A J Johnson
Journal:  Clin Radiol       Date:  2016-01-12       Impact factor: 2.350

7.  Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study.

Authors:  Elizabeth M Cespedes Feliciano; Valerie S Lee; Carla M Prado; Jeffrey A Meyerhardt; Stacey Alexeeff; Candyce H Kroenke; Jingjie Xiao; Adrienne L Castillo; Bette J Caan
Journal:  Cancer       Date:  2017-09-07       Impact factor: 6.860

Review 8.  Body composition changes in patients with head and neck cancer under active treatment: a scoping review.

Authors:  Bárbara Ferrão; Pedro Miguel Neves; Teresa Santos; Manuel Luís Capelas; Antti Mäkitie; Paula Ravasco
Journal:  Support Care Cancer       Date:  2020-06-13       Impact factor: 3.603

9.  Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib.

Authors:  Tim A Labeur; Jeroen L A van Vugt; David W G Ten Cate; R Bart Takkenberg; Jan N M IJzermans; Bas Groot Koerkamp; Robert A de Man; Otto M van Delden; Ferry A L M Eskens; Heinz-Josef Klümpen
Journal:  Liver Cancer       Date:  2018-11-02       Impact factor: 11.740

10.  Skeletal muscle-specific over-expression of the nuclear sirtuin SIRT6 blocks cancer-associated cachexia by regulating multiple targets.

Authors:  Sadhana A Samant; Vinodkumar B Pillai; Mahesh P Gupta
Journal:  JCSM Rapid Commun       Date:  2020-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.